Wednesday, 12 February 2014

Chillies in the brain: microglial activation in MS

Chillies in the brain: Is progressive MS due to hot microglia? #MSblog #MSResearch

"If you are a regular reader of this blog you will know that we believe that two processes underlie MS disease progression."

"(1) Acute or sudden inflammatory events that transect or shred axons and nerves. This occurs acutely in a narrow time window that probably lasts days to weeks; we refer to this as the inflammatory penumbra. We are testing acute neuroprotection in this widow with our phenytoin in acute optic neuritis trial. This acute damage occurs in association with with relapses and focal MRI lesions."

Hot microglia are like chillies in the brain!

"(2) The second process is more delayed and occurs over months to years. We think this second process may be primed by acute focal autoimmune inflammation, or by another process - possibly a viral infection. In other words we still don't know if this is a primary or secondary event. What is important is that this delayed slow neurodegeneration appears to independent of the focal autoimmune process and is driven by cells in the brain called microglia. We refer to them as 'hot microglia', hence the analogy with chillies in the brain. What is emerging is that we now have drugs that work downstream of autoimmune inflammation and target these hot microglia; examples are laquinimod, ibudilast, sodium channel blockers, BG12, etc. This is why we are testing these compounds on the neurodegenerative processes that drive progressive MS. We are about to start testing oxcarbazepine, as sodium channel blocker, in the PROXIMUS trial, and ibudilast in the MS-SMART and NIH funded studies. Teva announced last year that they are taking laquinimod forward in progressive MS. Biogen-Idec have yet to commit to testing BG12 in progressive MS, but I suspect they will. If any Biogen-Idec employees are reading this post may you would be prepared to comment on this?"

"The study below helps confirm the 'hot microglia' hypothesis. It uses a very clever imaging technique that is able to detect hot micoglia in the brains of MSers. I was actually on the original paper looking at this marker in MSers. I recall recruiting, examining and consenting all the subjects for that study; that was almost 20 years ago when I was doing my PhD."

Banati et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. 2000 Nov;123 ( Pt 11):2321-37.

Activated or hot microglia

"What this study below shows is that the black holes on T1 MRI are hot with activated microglia. We know that black hole lesions on T1 MRI are more destructive lesions with greater loss of axons and nerves and in progressive MSers the amount of hot microglia correlated with disability. What was interesting is that in the relapsing MSer group hot microglia were everywhere and correlated inversely with lesion volume; the more hot microglia the fewer and smaller the focal lesions. This is a result that is counter intuitive. I wonder what it means? It could mean that the hot microglia are the primary pathology, the initial event, and that the focal lesions are secondary in response to what is causing the diffuse pathology. This interpretation would support the hypothesis that MS is due to some diffuse neurodegenerative process and that the focal autoimmune lesions are secondary. How can we test this hypothesis? We are already doing this in the alemtuzumab extension studies. If MSers treated early with alemtuzumab and are rendered NEDA (no evident disease activity) for decades and never come back with SPMS then it is unlikely that MS is a diffuse neurodegenerative disease; in other words these MSers will be cured of their autoimmune disease by early induction therapy. This why alemtuzumab is such and important treatment. If on the other hand MSers treated early with alemtuzumab and are rendered NEDA (no evident disease activity) for decades and then present later with SPMS, MS is likely to be an primary neurodegenerative disease and the autoimmune response is secondary. I sincerely hope the former pans out to be the case, but will not be surprised if the latter turns out to be the reality. I am an autoimmune sceptic when it comes to MS. I hope this post makes sense to you."

Epub: Giannetti et al. Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. Neurobiol Dis. 2014 Feb 5.

Background: The pathophysiological correlates and the contribution to persisting disability of hypointense T1-weighted MRI lesions, black holes (BH), in multiple sclerosis (MS) are still unclear. 


Objectives: In order to study the in vivo functional correlates of this MRI finding, we used 11C-PK11195 PET (PK-PET) to investigate changes in microglial activity. 

Methods: Ten relapsing and 9 progressive MS subjects had a PK-PET scan and a MRI scan alongside a full clinical assessment, including the expanded disability status scale (EDSS) for evaluation of disability. We studied the PK binding potential of the specifically bound radioligand relative to the non-displaceable radioligand in tissue (BPND) in T1 BHs. 

Results: Out of a total of 1,242 BHs identified, 947 were PK enhancing. The PKBPND was correlated with the EDSS (r=0.818; p<0.05) only in the progressive group. In the relapsing MSers there was an inverse correlation between PKBPND and BH total lesion volume in whole brain (r=-0.781; p<0.05). When progressive MSers were grouped according to the disability outcome at 2years from the PK-PET scan, the total PKBPND in BHs was found to be a significant outcome predictor of disability (p<0.01). 

Conclusions: Our findings show that relapsing and progressive MSers have heterogeneous patterns of PKBPND in T1 BHs and indicate that BHs are not just "holes" representing loss of axons and myelin, but display inflammatory activity in the form of activated microglia. The significant association between PKBPND, neurological impairment and outcome in progressive subjects supports a role for activated microglia in disability progression.

The 20-year alemtuzumab experiment; are you prepared to wait for the answer?

CoI: multiple

16 comments:

  1. Great post; very clear. I now know why you are so excited about alemtuzumab and induction therapies. Are you actually saying that we may be able to cure MS?

    ReplyDelete
    Replies
    1. Re: "Are you actually saying that we may be able to cure MS?"

      Yes, if MS is an autoimmune disease then rebooting your immune system should theoretically be able to cure you. This is what is being tested with alemtuzumab and bone marrow transplantation programmes and would have been tested with cladribine had it survived. You may be interested in reading my previous post on this topic:

      http://multiple-sclerosis-research.blogspot.co.uk/2013/02/neda-defining-cure.html

      Please note that rebooting your immune system with alemtuzumab may not work in all people in particular if treatment is delayed. It is clear that between 30-50% of MSers treated with 2 courses of alemtuzumab will need additional courses to render them NEDA. The NEDA data from the 2-year alemtuzumab trials is not relevant; you need to rebaseline MSers at about 6 months after the second course of treatment; i.e. in the period were you expect the drug to be working. Disease activity before the second course and before the drug is working is really meaningless. In comparison, disease activity on a maintenance drug tells you the drug is not working.

      Delete
    2. Why do you not believe that mitochondrial dysfunction is at the heart of neurdegeneration? Could all of these eminent researchers be wrong?

      http://www.ncbi.nlm.nih.gov/pubmed/24369898

      Delete
    3. it may be these ideas are not distinct as the inflammatory response can condition the mitochondrial problem

      Delete
  2. Looks like existing SPMSers are going to be parked and conveniently forgotten about. There are a lot of us and probably growing

    ReplyDelete
    Replies
    1. Re: "Looks like existing SPMSers are going to be parked and conveniently forgotten about. There are a lot of us and probably growing."

      Not at all; we are doing several studies in SPMS. I am simply being realistic in stating that the hurdle is high one. It is better to treat the processes underlying progressive MS before you enter the SP stage and have more to gain. An effective neuroprotective agent in SPMS is unlikely to correct the deficits acquired; I suspect it will simply slow the rate of progression or flat line you at your current level of disability.

      Delete
  3. Prof G,

    are there any studies looking at the imaging activity of microglia in those on DMTs versus those not?

    I can't claim to understand the ins and outs of these studies as the findings in RRMS seem counter intuitive. Is there a way the microglia are being set up to be hot due to previous inflammation due to other inflammatory cells? Does the statement in your paper that you cite that activity can be seen in the lateral geniculate body after optic neuritis mean that the optic neuritis happens first, then the microglia become hot? (Or is it something else entirely happening?).

    You say you are an inflammatory skeptic - do you think there's a greater than 50:50 chance MS is primarily inflammatory?

    ReplyDelete
    Replies
    1. Re: "are there any studies looking at the imaging activity of microglia in those on DMTs versus those not?"

      Not aware of any, but some on laquinimod are planned. At the last ECTRIMS and animal study was presented on the impact of fingolimod on hot microglia; it reduced hot microglia.

      Delete
    2. Re: "You say you are an inflammatory skeptic - do you think there's a greater than 50:50 chance MS is primarily inflammatory?"

      I think MS is caused by a virus and the immune response is in response to a virus. I would therefore say that the inflammation is secondary.

      Delete
  4. Why not use the HiCy process to re-boot the immune system?

    ReplyDelete
  5. Prof G,

    Slightly depressing post for me. I had my first Alemtuzumab some 8 years ago and on the basis of no relapses, no activity seen on MRI and stable EDSS scores would assume that I am NEDA. However, this may not be enough and I sense from your post that sometime in the future, I may join the SPMS club. Is there anything else I can do to prevent this? I'm not too happy that I took the risks with a highly effective treatment yet am really just being used to test various hypotheses. Surely with superpowerful MRIs, pathology studies, the brain bank etc. we can get an answer sooner? I thought your theory was EBV infected B cells in the CNS and, for whatever reason, the immune sytem starts atacking these cells leaving damage (some damage at the time of the attack and other damage follows some time afterwards as the cells die off). I would guess that those who require additional courses of Alemtuzumab e.g. 5 years later, are cases where the EBV infected B cells are again not adequately controlled by the immune system i.e. the disease reactivates.

    ReplyDelete
    Replies
    1. Its not often that you hear a neuro mention the c word and that may be just that, but prof G is giving possibilities.

      In the animals the immune condition conditions the development of progression and if you stop the disease early it limits the development of the conditions that cause progression, so it may indeed be it.

      Delete
    2. Mouse Dr,

      do the animal models develop these hot microglia?

      Delete
    3. Re: " I may join the SPMS club. Is there anything else I can do to prevent this? "

      We simply don't know the answer to this and will have to wait to find out. In the future we may have additional add on therapies that you can take to tackle this process.

      Delete
  6. Why again is this just for SPMS'ers honestly, PPMS'ers are left without any hope

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.